- Home
- MESO
MESO
Mesoblast Limited
as 09-12-2025 4:00pm EST
Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.
| Founded: | 2004 | Country: | Australia |
| Employees: | N/A | City: | N/A |
| Market Cap: | 1.3B | IPO Year: | N/A |
| Target Price: | $18.00 | AVG Volume (30 days): | 230.7K |
| Analyst Decision: | Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.08 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.00 - $22.00 | Next Earning Date: | 08-28-2025 |
| Revenue: | $17,198,000 | Revenue Growth: | 191.39% |
| Revenue Growth (this year): | 293.59% | Revenue Growth (next year): | 218.64% |
Latest Mesoblast Limited News
MESO Breaking Stock News: Dive into MESO Ticker-Specific Updates for Smart Investing
GlobeNewswire
3 months ago
Mesoblast Maintains Momentum With FDA on Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure and Label Extension for Ryoncil® in Adults With GvHD
Simply Wall St.
3 months ago
Mesoblast (ASX:MSB) Gains 15% In One Week With US FDA Orphan-Drug Approval
MT Newswires
4 months ago
Mesoblast Receives 7-Year FDA Orphan Drug Exclusivity for Ryoncil in Pediatric Inflammatory Disease
GlobeNewswire
4 months ago
FDA Provides Seven Years of Orphan-Drug Exclusive Approval for Ryoncil®
Simply Wall St.
4 months ago
Mesoblast Limited's (ASX:MSB) market cap dropped AU$96m last week; Individual investors bore the brunt
GlobeNewswire
4 months ago
Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2025
GlobeNewswire
5 months ago
Mesoblast Appoints Corporate Finance Leader Lyn Cobley To Board
MT Newswires
5 months ago
Mesoblast Expands Payer Coverage for Ryoncil
Compare MESO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MESO Mesoblast Limited - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.